NASS 2020: Medtronic Announces First Patient Implant With InterStim Micro, Adaptix Interbody System Launch
Medtronic’s next-generation InterStim Micro system for overactive bladder is more competitive with Axionics’ r-SNM system, according to an analyst. Medtronic continues to innovate as its former CEO announces retirement.
You may also be interested in...
The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.
Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.
The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.